Literature DB >> 18263992

The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.

Satoshi Anai1, Kogenta Nakamura, Myron N Chang, John Pendleton, Saif Yacoub, Charles J Rosser.   

Abstract

OBJECTIVE: To determine the compliance rate for treatment recommendations consistent with expectant management of inner-city men with prostate cancer.
METHODS: Twenty-seven out of 560 men who underwent biopsy of the prostate were found to harbor cancer and opted for expectant management. Clinic and hospital records were reviewed for adherence to follow-up schema.
RESULTS: Of the 27 men on expectant management, 22 men (82%) adhered to strict follow-up schema. At 6-month follow-up, there were no significant changes in clinicopathologic features (e.g., prostate specific antigen (PSA), Gleason score, and stage). With a median follow-up of 12 months, only 2 men demonstrated a rise of more than 30% from baseline PSA (repeat biopsy demonstrated persistent low grade, low stage disease).
CONCLUSIONS: Our findings imply that expectant management may be feasible in inner-city settings. Thus, in subsequent expectant management trials, inner-city men should be actively recruited.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263992     DOI: 10.1353/hpu.2008.0024

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  3 in total

1.  Case Study of Noni Extract in Men with Very Low-Risk or Low-Risk Prostate Cancer.

Authors:  Yosuke Hirasawa; Ian Pagano; Jeffrey Huang; Yuka Sasaki; Kaoru Murakami; Charles J Rosser; Hideki Furuya
Journal:  Hawaii J Health Soc Welf       Date:  2021-10

2.  How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.

Authors:  Stacy Loeb; Dawn Walter; Caitlin Curnyn; Heather T Gold; Herbert Lepor; Danil V Makarov
Journal:  J Urol       Date:  2016-03-02       Impact factor: 7.450

3.  Prostate cancer--to screen, or not to screen, is that the question?

Authors:  Charles J Rosser
Journal:  BMC Urol       Date:  2008-12-23       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.